-+ 0.00%
-+ 0.00%
-+ 0.00%

The Teva Ecopipam Phase III clinical trial reduced the risk of recurrence by 53%.

智通財經·08/19/2026 12:33:33
語音播報
The Teva Ecopipam Phase III clinical trial reduced the risk of recurrence by 53%.